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Background: Schwann cells are the myelinating glial cells of the peripheral nervous system and exert important
regenerative functions revealing them as central repair components of many peripheral nerve pathologies. Intravenous
immunoglobulins (IVIG) are widely used to treat autoimmune and inflammatory diseases including immune-mediated
neuropathies. Nevertheless, promotion of peripheral nerve regeneration is currently an unmet therapeutical goal. We
therefore examined whether immunoglobulins affect glial cell homeostasis, differentiation, and Schwann cell dependent
nerve regenerative processes.
Methods: The responses of different primary Schwann cell culture models to IVIG were investigated: immature
or differentiation competent Schwann cells, myelinating neuron/glial cocultures, and dorsal root ganglion explants.
Immature or differentiating Schwann cells were used to study cellular proliferation, morphology, and gene/protein
expression. Myelination rates were determined using myelinating neuron/glia cocultures, whereas axonal outgrowth
was assessed using non-myelinating dorsal root ganglion explants.
Results: We found that IVIG specifically bind to Schwann cells and detected CD64 Fc receptor expression on
their surface. In response to IVIG binding, Schwann cells reduced proliferation rates and accelerated growth of
cellular protrusions. Furthermore, we observed that IVIG treatment transiently boosts myelin gene expression
and myelination-related signaling pathways of immature cells, whereas in differentiating Schwann cells, myelin
expression is enhanced on a long-term scale. Importantly, myelin gene upregulation was not detected upon
application of IgG1 control antibodies. In addition, we demonstrate for the first time that Schwann cells secrete
interleukin-18 upon IVIG stimulation and that this cytokine instructs these cells to promote axonal growth.
Conclusions: We conclude that IVIG can positively influence the Schwann cell differentiation process and that
it enhances their regenerative potential.
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Schwann cells, the myelinating glial cells of the periph-
eral nervous system (PNS), play a crucial role in the gen-
eration, function and maintenance of peripheral nerves.
They provide electric insulation by the formation of
lipid-rich myelin sheaths around large caliber axons.
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unless otherwise stated.processes as they can quickly adapt to pathological situa-
tions, dedifferentiate, undergo proliferation, promote
axonal regeneration, redifferentiate, and restore myelin
sheaths [1]. In the injured PNS, a repair response is initi-
ated by Schwann cells in which they degrade and phago-
cytose extracellular myelin debris, attract macrophages
for further clearance, and provide axons a supportive
and attractive environment to grow along [2, 3]. A large
number of studies also demonstrated that Schwann cells
can interact with cells of the immune system and that
they exhibit immune cell properties, comprising antigenl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sion of complement components, and surface receptors
involved in pathogen recognition (reviewed in [4]). This
immune competence along with the plastic differenti-
ation potential of Schwann cells provide the PNS with a
certain regeneration capacity and further indicates that
these glial cells are central components of many, if not
all, nerve pathologies. Nevertheless, nerve regeneration
in the PNS faces limitations, in particular when it comes
to inflammatory and inherited neuropathies, or in per-
ipheral nerve pathologies induced by toxins, drugs, or in
diabetic patients [5–8]. For most of these neurological
conditions, functional restoration of damaged axonal
tracts and myelin sheaths represents the ultimate thera-
peutic goal which is, however, currently unmet. Intra-
venous immunoglobulins (IVIG) are generally used for
the treatment of immune deficiencies. Moreover, IVIG
are considered as first-choice therapy for acute or
chronic polyneuropathies [9]. IVIG consist of polyclonal
human immunoglobulin G (IgG) which is purified from
large pools of human plasma donations. IVIG’s exact
mode of action in the treatment of demyelinating auto-
immune diseases still needs to be defined but is most likely
based on several immunomodulatory mechanisms such as
interaction with Fc receptors (fragment crystallisable (Fc)),
binding to pathogenic antibodies/anti-idiotype effect, inhib-
ition of complement binding, suppression of proinflamma-
tory cytokines as well as modulation of T and B cells [9].
Therapeutic effects of IVIG have also been demonstrated in
demyelinating disease models of the PNS, e.g., experimental
autoimmune neuritis (EAN). Treatment with IVIG resulted
in the reduction of disease severity and accelerated recovery
[10, 11]. Although no current evidence exists indicating
that IVIG also directly affect Schwann cells, recent data
point to a role of endogenous antibodies in rapid myelin
clearance and axon regeneration after nerve injury [12].
In the central nervous system (CNS), however, immu-
noglobulins were shown to influence oligodendroglial
cells in that monoclonal oligodendrocyte-reactive im-
munoglobulin M (IgM) antibodies can enhance remyeli-
nation [13, 14]. Moreover, treatment of demyelinating
disease models with polyclonal human IgG and IgM
molecules directly enhanced oligodendrocyte differenti-
ation [15–17]. Fc receptors for IgM were found to be
expressed on mouse oligodendrocytes, their precursor
cells, and myelin, which suggests that IgM directly inter-
acts with glial cells [18].
Based on these observations, the aim of this study was
to determine whether immunoglobulins, in particular
IVIG, can directly interact with Schwann cells, whether
this influences cell homeostasis and maturation, and
could thus be used to promote nerve regeneration in dif-
ferent nerve pathologies. Using different models of cul-
tured non-differentiating and differentiating Schwanncells, we found that these cells are not only able to bind
IVIG but also respond to this stimulation with a pro-
moted maturation reaction as well as an increased po-
tential to support axonal outgrowth.
Methods
Schwann cell culture
Primary rat Schwann cells were isolated from Wistar rat
neonatal sciatic nerves according to previously published
protocols [19]. Schwann cells were grown on poly-D-lysine
(PDL; Sigma-Aldrich, Taufkirchen, Germany) coated flasks,
dishes or glass coverslips in Dulbecco’s modified Eagle’s
medium (DMEM) low glucose (Gibco, Karlsruhe,
Germany) supplemented with 10 % fetal bovine serum
(FBS; Lonza, Cologne, Germany), 2 mM L-glutamine
(Gibco), penicillin/streptomycine (Gibco), and 2 μM
forskolin (Sigma-Aldrich). shRNA-mediated suppres-
sion of the p57kip2 gene was done using a nucleofector
II device (Lonza, Basel, Switzerland), positively selected
by means of hygromycin resistance plasmid, all as pre-
viously described [20]. Cells were kept for up to 9 days
in medium supplemented with 50 μg/ml hygromycin B
(Invitrogen, Karlsruhe, Germany). Cellular proliferation
rates were determined either via 5-bromo-2′-deoxy-uridine
(BrdU; Roche Applied Sciences, Penzberg, Germany) in-
corporation or by their Ki67 immunopositivity. For the ana-
lysis of Schwann cell growth, IVIG and control buffer were
added to the culture medium 2 days post transfection and
treatment was pursued for 3 days under selection condi-
tions. Morphological measurement of cell processes was
done on living cells (expressing fluorescent citrine protein,
green) on a Nikon Eclipse TE 200 microscope using NIS-
Elements AR 3.10 software (Nikon Instruments Europe BV,
Amsterdam, Netherlands).
Myelinating neuron/glia coculture
Mouse dorsal root ganglion (DRG) cultures were pre-
pared from embryonic day 15 (E15) C57BL6 mouse em-
bryos according to a previously published protocol [21].
DRG dissociation was performed in 0.05 % trypsin
(Gibco) and 0.05 % collagenase (Sigma-Aldrich) for 20
min at 37 °C. Dissociated DRGs were resuspended in 40
μg/ml deoxyribonuclease I (Sigma-Aldrich), and the di-
gestion was stopped with L15 Leibovitz’s medium
(Gibco) containing 10 % horse serum (Gibco). For each
condition approximately 500000 cells were seeded onto
one collagen (Becton-Dickinson, Franklin Lakes, NJU,
USA) coated x-well tissue culture chamber (Sarstedt,
Nümbrecht, Germany) and incubated in growth medium
at 10 % CO2 for 4 to 5 days. Myelination was induced by
changing to mouse myelination medium [21] supple-
mented with 20 mg/ml dialysed IVIG or dialysed control
buffer. After 7 days of buffer/IVIG treatment, cultures
were fixed with 4 % paraformaldehyde (PFA, Merck,
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protein (MBP) and β-tubulin (TUJ1). MBP positive in-
ternodes were counted in both conditions and the aver-
age number was determined.
Non-myelinating DRG explant cultures
DRG were dissected from E17/E18 Wistar rat embryos,
cut into two to four explants and plated on glass cover-
slips coated with 1 mg/ml PDL and 13 μg/ml laminin
(Sigma-Aldrich). Explants were cultured for 24 h as fol-
lows: (a) non-conditioned Schwann cell medium alone
or supplemented with different concentrations of rat re-
combinant interleukin-18 (rrIL-18 10 ng/ml, 25 ng/ml,
and 50 ng/ml; R&D Systems, Wiesbaden-Nordenstadt,
Germany); (b) Schwann cell conditioned medium alone
or Schwann cells treated with 10 ng/ml, 25 ng/ml, or 50
ng/ml rrIL-18 for 3 days; and (c) conditioned medium of
Schwann cells treated with either dialysed control buffer
or 20 mg/ml dialysed IVIG preparations for 3 days.
Axons were visualized using neurofilament (NF) immuno-
fluorescence. For quantification of axon outgrowth, mi-
croimages were taken (AxioVision software; C. Zeiss,
Mainz, Germany) and axonal length was measured
from the borders of the inner DRG core to the maximal
axon spread using ImageJ software (National Institutes
of Health, USA).
Animal research according to ARRIVE guidelines
For this study, no animal in vivo experiments were per-
formed. For the generation of primary cell cultures derived
from embryonic and neonatal rats and mice (animal sacri-
fice and tissue elevation), we received approval by the local
animal facility of the Heinrich-Heine-University (registra-
tion numbers O82/12, O69/2011, O53/11) in compliance
with the German Animal Protection law (State Office, En-
vironmental and Consumer Protection of North Rhine-
Westphalia, LANUV NRW). For primary Schwann cells,
we used P0 (postnatal day 0) Wistar rats of either sex; for
myelinating neuron/glia cocultures, we used E15 (embry-
onic day 15) C57BL6 mouse embryos of either sex; and for
non-myelinating DRG explant cultures, E17/18 (embryonic
day 17/18) Wistar rat embryos of either sex were used.
Adult C57BL6 mice and Wistar rats giving rise to pups and
embryos were grown and kept in the local animal facility.
Animals were housed under standard conditions with a
12 h light/12 h dark cycle. Water and food were available
ad libitum.
Immunoglobulin preparations
Gammagard Liquid (Immune Globulin Intravenous
(Human)) 10 % containing 100 mg/ml protein was used
(Baxter Healthcare Corporation, Westlake Village, CA,
USA). The majority of the experiments were performed
with IVIG lot LE12J270AB. Of note, two further IVIG lots(LE12L068AB; LE12L341AA) were tested and showed simi-
lar results in binding assays and functional analyses. In all
experiments, IVIG were used at a final concentration
of 20 mg/ml protein. Gammagard Liquid formulation
buffer (0.25 M glycine, pH 4.5) was included as a corre-
sponding control. F(ab′)2 fragments (fragment antigen-
binding (Fab)) were generated from Gammagard Liquid
(lot LE12L341AA) by incubation with pepsin (Sigma-
Aldrich) at pH 4 and 37 °C under pyrogenic-free con-
ditions. The reaction was halted by changing to pH 7,
then the F(ab′)2 fragments were purified using size ex-
clusion chromatography, filtered and adjusted to a
final concentration of 31 mg/ml in 0.25 M glycine buffer,
pH 4.5. The resulting F(ab′)2 fraction revealed an endotoxin
concentration of 0.436 EU/ml and 2.3 % of Fc binding in
comparison to IVIG was determined. The following human
monoclonal antibodies were used as IgG1 controls: Avastin
(Roche Pharma, Grenzach-Wyhlen, Germany), Herceptin
(Roche Pharma), and Synagis (Abbott SRL, Campoverde di
Aprilia, Italy) all at final concentrations of 20 mg/ml.
Prior to application, all antibody preparations (IVIG,
F(ab′)2, IgG1), as well as the corresponding control
buffers, were dialysed overnight at 4 °C to non-
supplemented DMEM using Slide-A-Lyzer Dialysis
Cassette 3.5K MWCO (molecular weight cut-off;
Thermo Scientific, Rockford, IL, USA) according to the
manufacturer’s protocol. Dialysis was performed in
order to balance minor effects, which resulted from the
IVIG formulation buffer. Of note, the distribution of
IgG monomers, dimers, and oligomers was analyzed in
IVIG preparations before and after dialysis by size ex-
clusion chromatography (SEC-HPLC). An average of
89.35 ± 1.16 % monomers, 10.53 ± 1.14 % dimers, and
0.12 ± 0.02 % oligomers was found, which changed to
87.32 ± 1.97 % monomers, 12.78 ± 1.66 % dimers, and
0.15 ±0.05% oligomers after dialysis and subsequent
storage of IVIG in cell culture media for 1–7 weeks.
However, a number of initial experiments were per-
formed with non-dialysed IVIG and revealed them to
be as effective as dialysed ones regarding proliferation,
gene expression, and morphological maturation. For
IVIG binding studies, Schwann cells were plated onto
glass coverslips, decorated with IVIG and control buffer
for 24 hours in culture, then fixed with 4 % PFA and
subjected to immunostaining. Decoration of Schwann
cells with purified F(ab′)2 fragments was performed for
4 h. Purified F(ab′)2 fragments were used at an equimolar
concentration corresponding to 5 mg/ml IVIG. The low
molar concentration was used to prevent aggregate forma-
tion. Immunocytochemical staining and visualization were
performed directly after cell fixation applying Cy3- or Alexa
Fluor 488-conjugated secondary antibodies specific to hu-
man F(ab′)2 or human Fc gamma fragments (all Jackson
Immuno Research Laboratories, Suffolk, UK) for 4 h at
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4′,6-diamidino-2-phenylindole (DAPI).
RNA isolation, cDNA synthesis, and quantitative RT-PCR
analysis
Total RNA was extracted from rat cultured Schwann cells
using RNeasy Mini Kit (Qiagen, Hilden, Germany), and
cDNA synthesis was performed by means of the High Cap-
acity cDNA reverse transcription kit (Applied Biosystems,
Darmstadt, Germany) using random hexamer primers.
Quantitative RT-PCR gene expression measurement was
assessed using an ABI PRISM 7900HT sequence detection
system and SybrGreen universal master mix (Applied Bio-
systems). Relative gene expression levels were determined
according to the ΔΔCt method (Applied Biosystems) using
both glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and ornithine decarboxylase (ODC) as reference genes.
Specific primer sequences were designed with the Primer
Express 3.0.1 software (Applied Biosystems) and tested
for specificity by amplicon melt curve analysis. Primer
sequences for the detection of GAPDH, ODC, MBP,
Pmp22 (peripheral myelin protein-22), Sox10 (SRY-related
HMGbox-10), Krox20/Egr2 (early growth response-2), and
Oct6 (octamer-binding transcription factor-6) have previ-
ously been published [20] whereas the following additional
primers were used: myelin protein zero (Mpz/P0) P0_fwd
ACCTTCAAGGAGCGCATCC; P0_rev GCCATCCTTCC
AGCTAGGGT; periaxin (Prx) Prx_fwd CGCCCGTGTGT
TCTTTGAG; Prx_rev AGGGCTCGGCACATTGC; per-
ipheral myelin protein 2 (Pmp2) Pmp2_fwd TGCAGAAG
TGGGATGGTAAAGA; Pmp2_rev TCCACTACCATTTT
CCCATCCA; proteolipid protein 1 (Plp1) Plp1_fwd CTTT
GGAGCGGGTGTGTCAT; Plp1_rev TGTCGGGATGTC
CTAGCCAT; connexin 32 (Cx32) Cx32_fwd CCTCCGGC
ATCTGCATTATC; Cx32_rev AGGCCCGGATGATGAG
GTA; myelin associated glycoprotein (Mag) Mag_fwd CGC
CTTTGCCATCCTGATT; Mag_rev TGTGACGTTCTTT
TTTCTTCTTGTCT; monocyte attractant protein-1
(Mcp-1) Mcp-1_fwd ATGATCCCAATGAGTCGGCT;
Mcp-1_rev CCTGCTGCTGGTGATTCTCTT; interleukin-
18 (IL-18) IL-18_fwd TGTGTTCGAGGACATGCCTG;
IL-18_rev GTCTGGGATTCGTTGGCTGT; Fc frag-




Schwann cells, myelinating neuron/glia cocultures, and
DRG explants were fixed with 4 % PFA. Unspecific staining
was blocked with either 2 % normal rabbit serum (NRS;
Invitrogen) or 10 % normal goat serum (NGS; Sigma-
Aldrich) in 0.5 % bovine serum albumin (BSA, Carl Roth,
Karlsruhe, Germany) and 0.5 % Triton X100 (Sigma-
Aldrich). Cells were then incubated with primaryantibodies in phosphate-buffered saline (PBS; Sigma-
Aldrich) supplemented with 2 % NRS/NGS overnight
at 4 °C. Myelinating neuron/glia cocultures were
blocked in 10 % NGS with 1 % Triton X100 and incubated
with primary antibodies in PBS supplemented with 10 %
NGS and 0.1 % Triton X100 overnight at 4 °C. DRG
explants were blocked in 5 % low background solution
(Inotech Biosystems, Brandon, FL, USA) and 0.1 % Triton
X100 and then incubated with primary antibodies diluted
in the same blocking buffer overnight at 4 °C. The following
primary antibodies were used: goat anti-CD64 (R&D Sys-
tems; 1:500), rabbit anti-Ki67 (Abcam, Cambridge, UK;
1:100), rabbit anti-cleaved caspase 3 (Cell Signaling
Technology, Boston, MA, USA; 1:100), mouse anti-
MBP (Covance, Emeryville, CA, USA; 1:500), rabbit
anti-β-tubulin (Covance; 1:1000), and mouse anti-
neurofilament (Covance; 1:1000). Alexa Fluor 488- or
Alexa Fluor 594-conjugated secondary antibodies (Invi-
trogen) were used for visualization of the signal. They
were applied for 2 h at a dilution of 1:500 in PBS. Nu-
clei were visualized using DAPI. Stained cell cultures
were analyzed using an Axioplan 2 fluorescence micro-
scope (Zeiss, Jena, Germany) and Axiovision 4.2 soft-
ware (Zeiss).
Western blot analysis
Harvested cell pellets were lysed on ice with RIPA buffer
(Cell Signaling Technology) supplemented with Halt
protease and phosphatase inhibitor cocktail (Thermo
Scientific). Whole cell lysates were subjected to two
sonification cycles of 15 s each and then centrifuged at
14000×g for 10 min to obtain the soluble protein frac-
tion. Protein concentrations were determined using the
DC Protein Assay (BioRad, Munich, Germany). Samples
were subjected to standard sodium dodecyl sulfate (SDS)
gel electrophoresis and Western blotting using 4–12 %
RunBlue SDS gels (Expedeon, Cambridgeshire, UK) and
RunBlue Blot Sandwich nitrocellulose (Expedeon) fol-
lowing application of goat anti-CD64 (R&D Systems;
1:1000), mouse anti-GAPDH (Millipore, Temecula, CA,
USA; 1:1000 for Odyssey detection/1:4000 for horse-
radish-peroxidase (HRP) detection), mouse anti-P0 ([22];
1:500), rabbit anti-MBP (Millipore; 1:500), rabbit anti-
p38 mitogen-activated protein kinase (p38MAPK)
(1:1000), rabbit anti-phospho-p38MAPK (1:400), rabbit
ant-phosphatase and tensin homolog (PTEN) (1:2000),
rabbit anti-phospho-PTEN (1:1000), rabbit anti-serine-
threonine kinase (Akt) (1:4000), rabbit anti-phospho-Akt
(1:500), rabbit anti-c-Jun (1:1000), rabbit anti-phospho-c-
Jun (1:500) (all from Cell Signaling Technology), and mouse
anti-actin (Becton-Dickinson; 1:1000) primary antibodies.
Visualization of signals using IRDye 800CW donkey anti-
mouse (1:15000) and IRDye 800CW goat anti-rabbit anti-
bodies (1:10000) was done using an Odyssey infrared
Tzekova et al. Journal of Neuroinflammation  (2015) 12:107 Page 5 of 15imaging system scanner (both LI-COR Biosciences,
Lincoln, NE, USA). For visualization of signals using
peroxidase-labeled horse anti-mouse (Vector Labora-
tories, Burlingame, CA, USA; 1:5000), peroxidase-
labeled horse anti-goat (Vector Laboratories; 1:2000),
or HRP-linked goat anti-rabbit (Cell Signaling Tech-
nology; 1:2000) secondary antibodies, nitrocellulose
membranes were incubated for 5 min with SuperSignal
West Pico Chemiluminescent Substrate (Thermo Sci-
entific) and then exposed to a Amersham Hyperfilm
ECL (GE Healthcare, Buckinghamshire, UK) to detect
the HRP signal. Protein band quantifications were per-
formed using the Odyssey software. The intensity for
each band was determined and normalized to the intensity
of the GAPDH band of the corresponding probe.
ELISA
Culture media were collected and centrifuged at 2000 rpm
for 10 min (4 °C), frozen on dry ice, and stored at −80 °C
prior further analysis. ELISA measurements were per-
formed with non-diluted media supernatants using the rat
interleukin-18 ELISA kit (Invitrogen). Detection of the op-
tical density was done at 450 nm on an Infinite M200 Pro
plate reader (TECAN, Crailsheim, Germany).
Statistical analysis
Data are presented as mean +/− standard error of the
mean (SEM), and significance was assessed by two-sided
Student’s t test, unpaired comparison for means (Graph-
Pad Prism). Experimental groups were considered sig-
nificantly different at *p<0.05, **p<0.01, ***p<0.001; ns,
not significant. n represents the number of independent
experiments.
Results
Human immunoglobulins specifically bind to the rat
Schwann cell surface
Several studies indicate that immunoglobulins may directly
affect oligodendroglial cells, the myelinating glial cells of
the CNS. This interaction was shown to promote cellular
differentiation as well as remyelination [14, 16, 17] likely
based on the expression of an IgM-specific Fc receptor on
oligodendrocytes, their precursor cells, and myelin [18].
These observations prompted us to address the question
whether immunoglobulins also bind to Schwann cell sur-
faces. To this end, we used a dialysed human IVIG prepar-
ation for the decoration of alive, non-differentiating
primary rat Schwann cells in culture. By applying anti-
human F(ab′)2-specific and anti-human Fc gamma-specific
antibodies (i.e., F(ab′)2 fragments), we could demonstrate
that human immunoglobulins specifically bind on the
Schwann cell surface (Fig. 1a–f). Immunofluorescent sig-
nals corresponding to surface bound immunoglobulins
could mainly be detected around perinuclear regions.Similar binding patterns were observed upon decoration of
differentiating Schwann cells (data not shown), induced by
means of suppression of the p57kip2 gene [20], as well as
when further IVIG lots were used (data not shown). In
order to study the binding mode we used a preparation of
pepsin digested IVIG, which is enriched in human F(ab′)2
fragments, for Schwann cell decoration. These assays re-
vealed a related binding pattern (Fig. 1g) indicating that it
could be mediated via the Fab domains of the immunoglob-
ulins. As further controls, we then used two human mono-
clonal IgG1 antibodies (Avastin and Herceptin) for
decoration, revealing similar binding patterns on the
Schwann cell surface (data not shown). Altogether, these
observations suggest that IVIG binding (representing a
large number of different IgG of different specificities)
could take place either via Fab parts recognizing Schwann
cell epitopes or via Fc parts interacting with Fc gamma
receptors.
Schwann cells express CD64 encoding a high affinity
immunoglobulin receptor
Previous studies indicated that Fc gamma receptors (Fcgr),
in particular Fcgr3/CD16, can be found on human and rat
Schwann cells [23–25]. To further characterize Fc receptor
expression by rat Schwann cells, we performed quantitative
RT-PCR measurements of Fcgr1a/CD64, Fcgr2a/CD32a,
Fcgr2b/CD32b, and Fcgr3a/CD16 transcripts. Interestingly,
we could only detect expression of CD64 and furthermore
found it to be significantly upregulated in differentiation
competent rat Schwann cells (Fig. 2d). Notably, IVIG
stimulation led to a small downregulation of CD64 expres-
sion levels in non-differentiating Schwann cells, whereas in
differentiating cells CD64 expression was not influenced.
We next performed staining experiments on non-
permeabilized Schwann cells using a polyclonal CD64 anti-
body in order to confirm CD64 protein expression on the
cell surface. Specific staining signals were distributed all
over the surface of non-differentiating cells (Fig. 2a–c)
whereas staining on differentiating Schwann cells was
mainly located on the cell soma above the perinuclear re-
gion (Fig. 2e–g). The same polyclonal CD64 antibody was
then applied in Western blot analysis confirming CD64 ex-
pression and upregulation in differentiating cells (Fig. 2h).
Of note, the antibody was found to be specific as it also rec-
ognized a recombinant truncated version of rat CD64 (data
not shown) as well as a band of the same apparent molecu-
lar weight when full-length Fcgr1a/CD64 with fused flag-
tag was overexpressed in cultured Schwann cells (data not
shown).
IVIG stimulation affects Schwann cell proliferation and
growth of cellular processes
As a next step, we investigated whether IVIG exert an effect
on primary Schwann cell proliferation. Stimulation with
Fig. 1 IVIG bind specifically to the Schwann cell surface. a–g Living Schwann cells were decorated for 24 h with either dialysed control buffer
(ctrl) (a–c), 20 mg/ml dialysed IVIG (d–f), or dialysed F(ab′)2 fragments, corresponding to 5 mg/ml IVIG (g). After fixation, the cells were stained
against human F(ab′)2 (red) and human Fc parts (green), and nuclei were labeled with DAPI (blue). IVIG and F(ab′)2 fragments binding could be
detected by means of co-immunostaining (a, d, g) or single staining against human F(ab′)2 (b, e) or human Fc fragments (c, f). Application of dialysed
control buffer (a–c) resulted in no staining. Scale bar, 50 μm. n = 8 for a–f, n = 4 for g
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proliferation rate of non-differentiating cells as revealed
by the reduction of incorporated BrdU (Fig. 3a–c) as
well as by staining against the proliferation marker
Ki67 (Fig. 3d). No evidence for a survival/apoptosis re-
lated role of IVIG could be generated by means of
staining for caspase-3 (data not shown). We could thenFig. 2 Schwann cells express the Fc gamma receptor CD64. On the surface of
(diff.; e–g), CD64 protein expression was detected. Differentiation was induced b
means of citrine (green-fluorescent protein) expression. Cell nuclei were visualized
(CD64) under differentiation promoting conditions as determined by quantitativ
comparison to control buffer (ctrl; black bars) decreased significantly the express
analysis of differentiating and non-differentiating Schwann cells, stimula
expression. Protein molecular weights are indicated in kDa (kilodalton).
significant, ***p < 0.001). Error bars represent SEM. Scale bar, 100 μm. nshow that IVIG treatment also affects Schwann cell
morphology. As we previously demonstrated that, upon
long-term suppression of the p57kip2 gene, Schwann
cells can undergo cellular differentiation in absence of
axons [20], we used this model for further examina-
tions regarding a potential influence of IVIG on matur-
ation processes. Along with an induction of myelinnon-differentiating (non-diff.; a–c) as well as differentiating Schwann cells
y means of p57kip2 suppression, and modulated cells were visualized by
by DAPI (blue). d Significant induction of rat Fcgr1a gene expression
e RT-PCR. Seven-day stimulation with 20 mg/ml dialysed IVIG (gray bars) in
ion of CD64 in non-differentiating Schwann cells, only (d). h Western blot
ted with both IVIG and control buffer (ctrl) confirmed CD64 protein
GAPDH expression was used for normalization. t test (ns, not
= 7 for a–c, n = 6 for e–g, n = 8 for d, n = 4 for h
Fig. 3 IVIG reduce proliferation rates and accelerate growth of cellular protrusions in differentiation competent Schwann cells. a–d Schwann cell
proliferation is reduced after 2 days of stimulation with 20 mg/ml dialysed IVIG (gray bars) compared to control buffer (ctrl) preparations (black
bars). a BrdU labeling was performed in the last 8 or 24 h (8h, 24h) of the IVIG treatment and evaluation of the percentage of BrdU/DAPI double
positive (BrdU+) nuclei compared to total number of DAPI nuclei revealed a significant reduction of proliferating cells. b, c Representative photographs of
DAPI (blue) and BrdU (green) labeled nuclei after 8 h BrdU pulse of control buffer b and IVIG c stimulated cells. d Staining against the
proliferation markers Ki67 and determination of the percentage of Ki67/DAPI double positive (Ki67+) nuclei in relation to the total number
of DAPI positive nuclei. e–g Quantification of the average Schwann cell protrusion lengths revealed significantly accelerated growth of
cellular processes in early stages of the differentiation process. e The cell processes of p57kip2 suppressed cells (diff.) were found to be
significantly longer after 3 days (3d) IVIG stimulation when compared to control buffer treated cells. However, no difference was observed
in non-differentiating (non-diff.) cells. f, g Representative photographs of differentiating citrine positive Schwann cells after 3 days control
buffer (f) or IVIG (g) treatment; cell processes are marked by white arrows. t test (ns, not significant, *p < 0.05, ***p < 0.001). Error bars represent SEM. Scale
bars, 100 μm in b, c; 200 μm in g. n = 4 for a–c, n = 2 for d, n = 10 for e–g
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also exhibit somatic and process growth [20]. We
found that a significantly increased mean length of
cellular processes could be observed in IVIG treateddifferentiating Schwann cells (Fig. 3e–g), after 5 days
following p57kip2 suppression and 3 days of IVIG
stimulation, while non-differentiating cells did not
respond.
Tzekova et al. Journal of Neuroinflammation  (2015) 12:107 Page 8 of 15IVIG stimulation induces myelin expression and activates
maturation related signaling pathways
Next, we investigated whether IVIG treatment affects the
expression of essential Schwann cell transcription factors,
myelin (−related) genes, and signaling molecules. To thisFig. 4 Short term IVIG effect on myelin gene expression and signaling mol
Schwann cells (non-diff.) were performed after 1 and 3 days of IVIG, IgG1 co
RT-PCR measurements of myelin gene expression showed consistent and s
with 20 mg/ml dialysed IVIG (gray bars) as opposed to control buffer (black bars
diminished. i–k Gene expression of important Schwann cell differentiat
stimulation. l Application of the human IgG1 Synagis (20 mg/ml, dialysed) did
m,n Western blot analysis (representative experiments) of signaling pathways
phospho-Akt (p-Akt) 1 day after IVIG treatment. Differentiation inhibitors such as
upon IVIG stimulation. Expression of cJun (n) was not changed after IVIG incuba
indicated in kDa (kilodalton). t test (ns, not significant, *p < 0.05, **p < 0
n = 18 for a, b, n = 7 for c, d, g, n = 4 for e, h, n = 11 for f, n = 5 for i,end, the transcriptional regulation of Mpz/P0, Mbp, Prx,
Pmp22, Pmp2, Plp1, Cx32, and Mag (Fig. 4a–h) was exam-
ined. We found that stimulation of non-differentiating cul-
tured Schwann cells with dialysed IVIG led to a significant
upregulation of myelin gene expression within the first dayecules. a–l Gene expression measurements of non-differentiating
ntrol (IgG1 ctrl), and control buffer (ctrl) treatment. a–h Quantitative
ignificant upregulation of myelin genes after 1 day (1d) stimulation
) stimulations. Myelin gene expression after 3 days (3d) IVIG stimulation was
ion-related transcription factors was also increased upon 1 day IVIG
not affect MBP gene expression. GAPDH was used for normalization.
related proteins revealed an increase in differentiation associated
phosphorylated forms of p38MAPK (m) or PTEN (n) were downregulated
tion. Actin was used for normalization and protein molecular weights are
.01, ***p < 0.001). Error bars represent SEM. Number of experiments:
j, k, n = 3 for l, n = 2 for m, n
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was transient and restricted to the first 24 h of treat-
ment (Fig. 4a–h). Importantly, when these cells were
stimulated with three different human monoclonal
IgG1 antibodies such as Synagis (Fig. 4l), Avastin, or
Herceptin (data not shown), MBP (Fig. 4l), and Mpz/P0
(data not shown) expression was not increased, sug-
gesting that the IVIG specific effect cannot be attrib-
uted to the presence of IgG1 with unrelated specificity.
Consistent with the observed myelin induction, IVIG
treatment also transiently boosted expression of tran-
scription factors Sox10, Oct6, and Krox20/Egr2
(Fig. 4i–k), all of which were previously shown to be in-
volved in the regulation of the myelination process [26].
Schwann cell differentiation and peripheral myelin-
ation depend on activation/phosphorylation of the
serine-threonine kinase Akt, a process which is triggered
by phosphatidylinositol 3,4,5-trisphosphate (PIP3) as
product of the phosphatidylinositol 3-kinase (PIP3K)
[27]. On the other hand, PTEN catalyzes the opposite
reaction, the dephosphorylation of PIP3 to phos-
phatidylinositol 4,5-bisphosphate (PIP2), and can act
thereby as indirect inhibitor of Akt activation and mye-
lination [28]. Western blot analysis revealed increased
levels of phosphorylated Akt (Fig. 4m) and downregula-
tion of the phosphorylated PTEN protein (Fig. 4n) after
1 day of stimulation indicating that IVIG treatment initi-
ates differentiation events. This was accompanied by
downregulation of the phosphorylated form of p38
mitogen-activated protein kinase (p38MAPK; Fig. 4m), a
prominent inhibitor of Schwann cell differentiation [29].
On the other hand, expression of cJun and phospho-
cJun, an important negative regulator of Schwann cells
differentiation [30, 31] was not altered upon IVIG treat-
ment (Fig. 4n). Following the observation that differenti-
ation incompetent Schwann cells transiently benefit
from IVIG treatment, we then investigated to what de-
gree such treatment can influence the differentiation
process as such. For this purpose, we examined the mye-
lin expression of differentiation competent (p57kip2 sup-
pressed) cells upon IVIG treatment (Fig. 5a–l). Using
quantitative RT-PCR, we could show that despite robust
increases already after p57kip2 suppression (as previ-
ously shown in [20]), myelin gene expression was further
induced by IVIG (Fig. 5a–h). Transcript levels of Mbp,
Prx, Plp1, Cx32, and Mag were strongly induced upon
IVIG stimulation, whereas Mpz/P0 and Pmp22 tran-
script levels (Fig. 5a, d) were only mildly induced and
Pmp2 levels were found to be slightly downregulated
(Fig. 5e). Note that myelin gene induction could be ob-
served after a period of 7 days of IVIG treatment and
was therefore not limited to early phases, as shown for
differentiation incompetent cells (Fig. 4). As an excep-
tion, we found that upregulation of Plp1 and Cx32 wasnot restricted to early periods and could consistently be
observed also in non-differentiating cells after 3 and 7
days of stimulation (Figs. 4f, g and 5f, g). These gene in-
ductions were reflected by elevated levels of Mpz/P0 and
MBP proteins, two of the most abundant proteins of
peripheral myelin (Fig. 5i–l). We then studied the effects
of IVIG application on axon/Schwann cell interactions
by means of in vitro myelination (Fig. 5m–o). IVIG
stimulation was done concomitant to the initiation of
the myelination process and was performed for 7 days.
In order to evaluate to which extent immunoglobulin
treatment can modulate the generation of myelin
sheaths, neuron/glia cocultures were stained using anti-
MBP and anti-ß-tubulin antibodies (Fig. 5m, n) and
MBP positive internodes were counted (Fig. 5o). This
analysis revealed that in IVIG treated myelinating cocul-
tures significantly more internodes were generated as
compared to buffer treated cultures, indicating that IVIG
exert a positive effect on myelin expression as well as on
axonal wrapping process.
IVIG induced expression of interleukin-18
In order to identify further transcriptional changes in-
duced by IVIG treatment in rat Schwann cells, a Gene-
Chip Array analysis was performed on non-differentiating
and differentiating Schwann cells which have been stimu-
lated by IVIG or control buffer for 7 days. A detailed
description of IVIG regulated genes will be described
elsewhere; however, we found that one of the most
prominently upregulated genes was interleukin-18 (IL-18),
a proinflammatory cytokine belonging to the IL-1 fam-
ily [32]. According to the GeneChip data, IL-18 was signifi-
cantly upregulated in non-differentiating Schwann cells.
We therefore investigated this finding in greater detail and
validated transcript levels by means of quantitative real-
time RT-PCR (Fig. 6a). This analysis confirmed strong in-
duction in non-differentiating cells as well as that IVIG
treatment can induce IL-18 expression over a period of at
least 9 days (Fig. 6b). Moreover, by means of ELISA, we
could show that cultured Schwann cells also secrete ele-
vated IL-18 levels at days 1, 4, 7, and 9 upon IVIG stimula-
tion (Fig. 6d). Of note, although at late time points
differentiating Schwann cells were not showing an IVIG
dependent increase in IL-18 transcript levels (Fig. 6a), IL-18
protein levels were elevated in both Schwann cell popula-
tions after 4 and 7 days (Fig. 6c, e). In addition, we exam-
ined the transcriptional regulation of monocyte attractant
protein-1 (Mcp-1), a further proinflammatory molecule se-
creted by Schwann cells, which is involved in macrophage
attraction/activation during Wallerian degeneration [33, 34]
as well as in genetically induced demyelination [35]. We
found Mcp-1 transcript levels to be consistently upregu-
lated at later time points during IVIG stimulation of non-
differentiating Schwann cells (Fig. 6f).
Fig. 5 IVIG treatment induces myelin gene and protein expression. Differentiation competent Schwann cells respond to IVIG interaction by
increasing their myelin gene (a–h) and protein expression (i–l). Two days after differentiation was initiated, 20mg/ml dialysed IVIG and control
buffer (ctrl) were added to the culture medium. Treatment of differentiating (diff.) and non-differentiating (non-diff.) cells was pursued for 7 days,
with one medium change at day 4. a–h Quantitative RT-PCR revealed significant upregulation of most myelin genes after 7 days stimulation with
IVIG (gray bars) or control buffer (black bars). i–j Western blot analysis confirmed increased P0 (i, j) and MBP (k, l) protein expression after 7-day
stimulation of differentiating and non-differentiating Schwann cells. i, k representative Western-blots, j, l corresponding Odyssey quantifications.
Protein molecular weights are indicated in kDa (kilodalton). m–o Quantification of in vitro myelination revealed a significant increase of MBP positive
internodes (red) after 7 days IVIG treatment (o); β-tubulin staining (β-tub) is visualized in green.m, n Representative photographs of myelinating neuron/glia
cocultures treated with either control buffer (m) or IVIG (n). GAPDH was used as normalization control in all experiments. t test (ns, not
significant, *p < 0.05, **p < 0.01, ***p < 0.001). Error bars represent SEM. Scale bar, 100 μm. n = 10 for a, n = 8 for b, n = 4 for c, n = 7 for
d, e, n = 5 for f, h, n = 3 for g, n = 5 for i–j, k–l, n = 9 for m–o
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We observed that conditioned medium from Schwann
cells treated with IVIG over 3 days could significantly in-
duce neurite outgrowth of sensory neurons (Fig. 7a) as
revealed by in vitro neurite growth assays based on dor-
sal root ganglion (DRG) explant cultures as previously
shown [36]. Considering the here detected IL-18 expres-
sion by Schwann cells upon IVIG stimulation, we inves-
tigated whether this cytokine might contribute to this
effect. To test this possibility, DRG explants were given
medium that has been conditioned over 3 days by IL-18stimulated Schwann cells (Fig. 7b), or supplied with
medium freshly supplemented with recombinant IL-18
(Fig. 7c). Axonal outgrowth was measured 24 h after plating
by determining the average length of neurofilament-
positive neurites. As expected, Schwann cell condi-
tioned medium improved neurite outgrowth (compare
levels in Fig. 7a, b, vs. c; red dotted line). Importantly,
this positive growth effect was further potentiated in a
dose dependent way when medium was conditioned by
IL-18 treated Schwann cells (Fig. 7b, d–g). In cultures
treated with non-conditioned Schwann cell medium
Fig. 6 IVIG dependent expression and secretion of IL-18 and Mcp-1. a, c, e Two days after transfection, differentiating (diff.) and non-differentiating
(non-diff.) Schwann cells were stimulated for up to 7 days (7d) with 20 mg/ml dialysed IVIG or control buffer (ctrl) with one medium exchange at
day 4 (4d). At day 7, quantitative RT-PCR revealed a significant upregulation of IL-18 gene expression in non-differentiating cells (a) but not in differentiating
cells. However, ELISA determination revealed elevated secreted IL-18 protein levels at both time points, 4d and 7d, after IVIG stimulation (c, e). b, d Similarly,
induced IL-18 gene and protein expression levels could be observed when naive (non-transfected and therefore non-differentiating) Schwann cells were
IVIG stimulated as shown on time points 1d, 4d, 7d, and 9d. Of note, 4d medium was collected before the medium change. f Mcp-1 gene expression levels
were also upregulated after 4d, 7d, and 9d of IVIG stimulation. GAPDH was used as reference gene (a, b, f). t test (ns, not significant, *p < 0.05, **p < 0.01,
***p < 0.001). Error bars represent SEM. n = 7 for a, n = 3 for b, f, n = 3 for c, d, e
Tzekova et al. Journal of Neuroinflammation  (2015) 12:107 Page 11 of 15and freshly added IL-18, neurite growth was not af-
fected (Fig. 7c).
Discussion
IVIG have been used for more than two decades for the
treatment of demyelinating immune system disorders,
especially inflammatory neuropathies, and the possibly
underlying immunomodulatory effects have extensively
been described [9]. However, a direct effect of pooledimmunoglobulins on glial cells of the peripheral nervous
system, hence a potential regeneration associated role,
has not been shown so far. In this study, we could dem-
onstrate that IVIG specifically bind to the surface of pri-
mary Schwann cells and we also detected expression of a
high affinity Fc receptor on these cells. As a result of
IVIG binding, Schwann cell maturation was initiated
and promoted, and in the presence of axons an in-
creased number of internodes could be detected. Note
Fig. 7 Schwann cell dependent promotion of axonal outgrowth. a–g Average neurite growth lengths were determined 24 h after incubation of
rat DRG explants in culture medium of Schwann cells treated with control buffer (ctrl), IVIG, or different IL-18 concentrations. Three different culture media
were used: a culture medium conditioned by control buffer treated Schwann cells (black bar) and by cells stimulated with 20 mg/ml dialysed IVIG (gray
bar) for 3 days; b culture medium conditioned by Schwann cells treated with IL-18 over 3 days and c culture medium directly supplemented with IL-18
(non-conditioned). Quantification of neurite lengths (NF-positive) from the DRG core to the outer rim revealed extensive radial neurite outgrowth in
Schwann cell conditioned media (a, b) in comparison to non-conditioned culture media (c). Treatment of Schwann cells with IVIG further increased the
neuritic growth (a), and media conditioned by IL-18 treated Schwann cells also showed a positive, concentration dependent effect on outgrowth (b),
whereas direct addition of IL-18 to the culture medium did not exert any effect (c). d–g Representative DRG explants cultured in medium
conditioned by Schwann cell that were stimulated by different IL-18 concentrations; neurofilament (NF) staining is visualized in green. t test
(ns, not significant, ***p < 0.001). Error bars represent SEM. Scale bar, 200 μm. n = 3 for a, n = 5 for b, c, per experiment and condition
6–12 explants were evaluated. Red line marks the average neurite length in response to non-conditioned medium (0 ng/ml IL-18 in c)
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nevertheless able to induce robust transient molecular
reactions but could not maintain long-term alterations,
indicating that the need to either remove intrinsic in-
hibitory components [37] or to provide axonal contact
cannot be completely overcome by this treatment.
In addition, we here demonstrate for the first time that
Schwann cells secrete IL-18 and that production of this
cytokine is boosted upon IVIG stimulation. Functional
studies using DRG explants then revealed that IVIG and
IL-18 stimulated Schwann cells can both support axonal
outgrowth whereas direct IL-18 treatment of neurons
showed no effect. This suggests a fundamental contribu-
tion of this cytokine to restoration processes of injured
and diseased nerves. Whether IL-18 is solely responsible
for the IVIG-mediated neuritic growth effect remains to
be shown. It can therefore be concluded at this point
that IVIG cannot only positively influence Schwann cell
differentiation processes but that their regenerative po-
tential also benefits from this stimulation. As an IL-1
family member, IL-18 is considered a proinflammatory
cytokine, which is not only expressed by immune com-
petent cells such as T lymphocytes and macrophages but
also CNS cells such as microglia and astrocytes [38]. In
the PNS, elevated levels of IL-18 were shown to co-localize with activated macrophages in inflamed nerve
roots of EAN rats, as well as in serum and cerebrospinal
fluid of GBS patients [39]. IL-18 was also found to be
transiently induced after peripheral nerve injury. In these
nerves, IL-18 expression was assigned to macrophages
and supposed to mediate macrophage engagement for
effective myelin uptake [40]. In light of our findings,
IL-18 might therefore exert additional neuroprotective
and neurorestorative roles also in inflammatory nerve
conditions. It will be of interest to learn in future stud-
ies to what degree IL-18 can change the glial secretome
and to identify the nature of released axonal growth
factors.
On the other hand, an IVIG enforced/instructed inter-
action between Schwann cells and macrophages is fur-
ther suggested by the observed induction of the Mcp-1.
This chemokine is known to attract macrophages to the
site of injury in Wallerian degeneration and in CMT
models thus displaying a beneficial effect on the inflam-
mation process after nerve injury [41].
The underlying mode of action, especially concerning
the exact way immunoglobulins interact with Schwann
cell surface proteins, needs to be further explored and
might include multiple different mechanisms. Currently,
we hypothesize that both ways of surface recognition are
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recognize specific Schwann cell epitopes, whereas on the
other hand, Fc receptor binding could also occur, similar
to the described IVIG interactions with components of
the immune system [9]. Future studies must include a
determination to what degree glial reactions depend on
IgG monomers, dimers, or oligomers as they can occur
in solution as well as surface bound. According to our
SEC data, IgG dimers are present but their fraction did
not substantially change upon dialysis over time. Detec-
tion of CD64 receptor for high affinity IgG binding on
Schwann cells, as well the finding that IVIG-derived
F(ab′)2 fragments can also specifically interact with the
cell surface, support such a dual mode of action. Al-
though identification of maturation- and regeneration-
associated glial epitopes would constitute a major step
towards refined nerve repair approaches, such investiga-
tions must be reserved for future studies and will most
likely imply state of the art biochemical analyses. It is
therefore conceivable that a constellation similar to
oligodendroglial cells could develop, where expression of
an Fc receptor for IgM on mouse oligodendrocytes was
initially reported [18]. Whereas further studies showed
that pentameric IgM bind to oligodendroglial cells and
promote their differentiation, the recombinant human
autoantibody rHIgM22, of which vitronectin/fibronectin
receptor αvβ3 was identified as a potential target,
emerged from these studies and has now entered clinical
trials [42, 43]. Importantly, although polyclonal IgM
molecules turned out to be more potent inducers of
oligodendroglial differentiation and remyelination, hu-
man IVIG also promoted this process [15–17]. Never-
theless, one should be aware of possible xenoreactive
effects since in the current study we used human im-
munoglobulin preparations and examined their effect on
rat and mouse cell culture models. Future translations of
our findings will therefore include the study of IVIG’s
role in vivo as well as investigations using either rodent
immunoglobulins or human Schwann cells.
It is of interest to see that early studies already de-
scribed Fcgr3/CD16 receptor expression by human
Schwann cells [44, 23, 24]. Nevertheless, CD16 expres-
sion was found to be dependent on axonal contact and
at lower levels when compared to macrophages [45, 25].
This is in line with our data showing that differentiating
Schwann cells exhibited significantly higher CD64 recep-
tor levels as compared to non-differentiating cells.
Whether or not IVIG directly interact with CD64 on the
Schwann cell surface and thus this interaction contrib-
utes to the glial immunocompetence [4] remains to be
determined in future examinations. In order to deter-
mine the exact mode of IVIG action, digested/modified
fractions of IVIG could be used allowing only one pos-
sible way of surface binding. This along withinvestigations directed to determine immunoglobulin
complex formation on cell surfaces (vs. in solution)
could be of help to exclude the possibility that IgG bind
to non-biogenic surfaces and thus mimic immune
complexes.
Independent from the description of active components
and their appropriate partner proteins on Schwann cells,
the observation that immunoglobulin/glial cell interactions
take place and that, as a consequence, cellular maturation
is induced and a regenerative phenotype is promoted, is of
interest as such. Our observations might also reflect recent
findings on Wallerian degeneration related intrinsic (auto-)
antibodies, contributing to successful nerve repair [12].
However, a different mode of action was suggested as the
authors found immunoglobulins to bind degenerating mye-
lin and to promote macrophage-dependent clearance. Simi-
lar immune-related mechanisms have been proposed in
CMT1 models of inherited neuropathies [41].
Conclusions
Our findings might pave the way for future nerve repair
therapies, favored by a high safety profile of IVIG. It there-
fore remains to be shown in future studies to what degree
endogenous as well as therapeutically applied immunoglob-
ulins exert combinatorial effects including local immuno-
modulation, effective myelin opsonisation and true glial
modulation for functional nerve restoration. Given the cen-
tral role of Schwann cells for regeneration in most if not all
nerve pathologies, this strongly suggest that IVIG could be
used as supportive treatment for endogenous nerve repair
processes. As this is still an unmet therapeutic goal, a num-
ber of patients with various nerve pathologies could benefit
from such a treatment.
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